Radium-223 dichloride with enzalutamide for treating hormone-relapsed metastatic prostate cancer

Radium-223 dichloride in combination with enzalutamide are in clinical development for the treatment of hormone-relapsed metastatic prostate cancer. Hormone-relapsed metastatic prostate cancer occurs when prostate cancer, which has spread to other parts of the body, stops responding to hormonal treatment. Initially, treatments can control the cancer for months or years, but eventually, the cancer grows despite low testosterone levels. Symptoms may include frequent urination, urgency, difficulty urinating, tiredness, bone pain, and weight loss. Current treatment focuses on easing symptoms and helping people live longer, with approximately 53% of patients surviving five years.